Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL

Journal of Medicinal Chemistry

Volumn 56, Issue 13, 2013, Pages 5514-5540

  Sleebs, Brad E ^a,b   Kersten, Wilhemus J A ^a,b   Kulasegaram, Sanji ^a,b,c   Nikolakopoulos, George ^a,b   Hatzis, Effie ^a,b   Moss, Rebecca M ^a,b   Parisot, John P ^a,b,d   Yang, Hong ^a,b   Czabotar, Peter E ^a,b   Fairlie, W Douglas ^a,b   Lee, Erinna F ^a,b   Adams, Jerry M ^a,b   Chen, Lin ^a,b   Van Delft, Mark F ^a,b   Lowes, Kym N ^a,b   Wei, Andrew ^a,b,e   Huang, David C S ^a,b   Colman, Peter M ^a,b   Street, Ian P ^a,b   Baell, Jonathan B ^a,b,c   Watson, Keith ^a,b   Lessene, Guillaume ^a,b   more..

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 [ 2 [ ( 5 ( 3 NITROPHENYL)FURAN 2 YL)METHYLENE]HYDRAZINYL]BENZOTHIAZOLE; 2 [ 3 ( 5 ACETYLFURAN 2 YL)PHENYL]ACETIC ACID; 2 [ 5 [ 1 ( 2 (BENZO[D]THIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL]BENZOIC ACID; 2 CHLORO 5 [ 5 [ 1 ( 2 ( 6 BROMOBENZOTHIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL]BENZOIC ACID; 2 CHLORO 5 [ 5 [ 1 ( 2 ( 6 CHLOROBENZOTHIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL]BENZOIC ACID; 2 CHLORO [ 5 [ 1 ( 2 ( 6 (TRIFLUROMETHYL)BENZOTHIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL]BENZOIC ACID; 2 HYDRAZINO 1 METHYL 1H BENZIMIDAZOLE; 2 HYDRAZINYLBENZOXAZOLE; 3 ( 5 FORMYLFURAN 2 YL)BENZAMIDE; 3 [ 5 [ ( 2 (BENZO[D]THIAZOL 2 YL)HYDRAZONO)METHYL]FURAN 2 YL]BENZOIC ACID; 3 [ 5 [ 1 ( 2 (BENZO[D]THIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL] 2 CHLOROBENZOIC ACID; 3 [ 5 [ 1 ( 2 (BENZO[D]THIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL] 2 METHYLBENZOIC ACID; 3 [ 5 [ 1 ( 2 (BENZO[D]THIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL] 4 CHLOROBENZOIC ACID; 3 [ 5 [ 1 ( 2 (BENZO[D]THIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL]BENZOIC ACID; 3 [ 5 [ 1 ( 2 (BENZOTHIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL]BENZAMIDE; 4 [ 5 [ 1 ( 2 (BENZO[D]THIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL]BENZOIC ACID; 5 [ 5 [ 1 ( 2 (BENZO[D]THIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL] 2 AMINOBENZOIC ACID; 5 [ 5 [ 1 ( 2 (BENZO[D]THIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL] 2 CHLOROBENZOIC ACID; 5 [ 5 [ 1 ( 2 (BENZO[D]THIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL] 2 NITROBENZOIC ACID; 5 [ 5 [ 1 ( 2 (BENZO[D]THIAZOL 2 YL)HYDRAZONO)ETHYL]FURAN 2 YL]ISOPHTHALIC ACID; BENZOIC ACID DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; HYDRAZONE DERIVATIVE; METHYL 3 [ 5 [( 2 (BENZOTHIAZOL 2 YL)HYDRAZONO)METHYL]FURAN 2 YL]BENZOIC ACID; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; FIBROBLAST; HYDROPHOBICITY; IC 50; MOLECULAR WEIGHT; MOLECULE; NONHUMAN; SOLID TUMOR; SURFACE PLASMON RESONANCE;

ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BENZOTHIAZOLES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELLS, CULTURED; DRUG DISCOVERY; EMBRYO, MAMMALIAN; FIBROBLASTS; HYDRAZONES; KINETICS; MICE; MICE, KNOCKOUT; MODELS, CHEMICAL; MOLECULAR STRUCTURE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; SURFACE PLASMON RESONANCE;

EID: 84880180686     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400556w     Document Type: Article

References (53)

1. Cory, S.; Adams, J. M. Killing cancer cells by flipping the Bcl-2/Bax switch Cancer Cell 2005, 8, 5-6
2. Strasser, A.; Cory, S.; Adams, J. M. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases EMBO J. 2011, 30, 3667-3683
3. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer Cell 2000, 100, 57-70
4. Labi, V.; Erlacher, M.; Kiessling, S.; Villunger, A. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy Cell Death Differ. 2006, 13, 1325-1338
5. Villunger, A.; Labi, V.; Bouillet, P.; Adams, J.; Strasser, A. Can the analysis of BH3-only protein knockout mice clarify the issue of 'direct versus indirect' activation of Bax and Bak? Cell Death Differ. 2011, 18, 1545-1546
6. Leber, B.; Lin, J.; Andrews, D. W. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes Apoptosis 2007, 12, 897-911
7. Leber, B.; Lin, J.; Andrews, D. W. Still embedded together binding to membranes regulates Bcl-2 protein interactions Oncogene 2010, 29, 5221-5230
8. Lindsten, T.; Ross, A. J.; King, A.; Zong, W. X.; Rathmell, J. C.; Shiels, H. A.; Ulrich, E.; Waymire, K. G.; Mahar, P.; Frauwirth, K.; Chen, Y.; Wei, M.; Eng, V. M.; Adelman, D. M.; Simon, M. C.; Ma, A.; Golden, J. A.; Evan, G.; Korsmeyer, S. J.; MacGregor, G. R.; Thompson, C. B. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues Mol. Cell 2000, 6, 1389-1399
9. Wei, M. C.; Zong, W. X.; Cheng, E. H.; Lindsten, T.; Panoutsakopoulou, V.; Ross, A. J.; Roth, K. A.; MacGregor, G. R.; Thompson, C. B.; Korsmeyer, S. J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death Science 2001, 292, 727-730
10. Lessene, G.; Czabotar, P. E.; Colman, P. M. BCL-2 family antagonists for cancer therapy Nature Rev. Drug Discovery 2008, 7, 989-1000
11. Czabotar, P. E.; Lessene, G. Bcl-2 Family Proteins as Therapeutic Targets Curr. Pharm. Des. 2010, 16, 3132-3148
12. Souers, A. J.; Leverson, J. D.; Boghaert, E. R.; Ackler, S. L.; Catron, N. D.; Chen, J.; Dayton, B. D.; Ding, H.; Enschede, S. H.; Fairbrother, W. J.; Huang, D. C.; Hymowitz, S. G.; Jin, S.; Khaw, S. L.; Kovar, P. J.; Lam, L. T.; Lee, J.; Maecker, H. L.; Marsh, K. C.; Mason, K. D.; Mitten, M. J.; Nimmer, P. M.; Oleksijew, A.; Park, C. H.; Park, C. M.; Phillips, D. C.; Roberts, A. W.; Sampath, D.; Seymour, J. F.; Smith, M. L.; Sullivan, G. M.; Tahir, S. K.; Tse, C.; Wendt, M. D.; Xiao, Y.; Xue, J. C.; Zhang, H.; Humerickhouse, R. A.; Rosenberg, S. H.; Elmore, S. W. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Nature Med. 2013, 19, 202-208
13. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B. L.; Wendt, M. D.; Zhang, H. C.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435, 677-681
14. L J. Med. Chem. 2007, 50, 641-662
15. Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 2008, 68, 3421-3428
16. Park, C. M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K. C.; Nimmer, P.; Shoemaker, A.; Song, X.; Tahir, S.; Tse, C.; Wang, X.; Wendt, M.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S.; Elmore, S. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins J. Med. Chem. 2008, 51, 6902-6915
17. Chen, L.; Willis, S. N.; Wei, A.; Smith, B. J.; Fletcher, J. I.; Hinds, M. G.; Colman, P. M.; Day, C. L.; Adams, J. M.; Huang, D. C. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function Mol. Cell 2005, 17, 393-403
18. Mason, K. D.; Vandenberg, C. J.; Scott, C. L.; Wei, A. H.; Cory, S.; Huang, D. C. S.; Roberts, A. W. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 17961-17966
19. van Delft, M. F.; Wei, A. H.; Mason, K. D.; Vandenberg, C. J.; Chen, L.; Czabotar, P. E.; Willis, S. N.; Scott, C. L.; Day, C. L.; Cory, S.; Adams, J. M.; Roberts, A. W.; Huang, D. C. S. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized Cancer Cell 2006, 10, 389-399
20. Zhang, H.; Nimmer, P. M.; Tahir, S. K.; Chen, J.; Fryer, R. M.; Hahn, K. R.; Iciek, L. A.; Morgan, S. J.; Nasarre, M. C.; Nelson, R.; Preusser, L. C.; Reinhart, G. A.; Smith, M. L.; Rosenberg, S. H.; Elmore, S. W.; Tse, C. Bcl-2 family proteins are essential for platelet survival Cell Death Differ. 2007, 14, 943-951
21. Mason, K. D.; Carpinelli, M. R.; Fletcher, J. I.; Collinge, J. E.; Hilton, A. A.; Ellis, S.; Kelly, P. N.; Ekert, P. G.; Metcalf, D.; Roberts, A. W.; Huang, D. C.; Kile, B. T. Programmed anuclear cell death delimits platelet life span Cell 2007, 128, 1173-1186
22. Tahir, S. K.; Yang, X. F.; Anderson, M. G.; Morgan-Lappe, S. E.; Sarthy, A. V.; Chen, J.; Warner, R. B.; Ng, S. C.; Fesik, S. W.; Elmore, S. W.; Rosenberg, S. H.; Tse, C. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737 Cancer Res. 2007, 67, 1176-1183
23. Beroukhim, R.; Mermel, C. H.; Porter, D.; Wei, G.; Raychaudhuri, S.; Donovan, J.; Barretina, J.; Boehm, J. S.; Dobson, J.; Urashima, M.; Henry, K. T. M.; Pinchback, R. M.; Ligon, A. H.; Cho, Y.; Haery, L.; Greulich, H.; Reich, M.; Winckler, W.; Lawrence, M. S.; Weir, B. A.; Tanaka, K. E.; Chiang, D. Y.; Bass, A. J.; Loo, A.; Hoffman, C.; Prensner, J.; Liefeld, T.; Gao, Q.; Yecies, D.; Signoretti, S.; Maher, E.; Kaye, F. J.; Sasaki, H.; Tepper, J. E.; Fletcher, J. A.; Tabernero, J.; Baselga, J.; Tsao, M.; Demichelis, F.; Rubin, M. A.; Janne, P. A.; Daly, M. J.; Nucera, C.; Levine, R. L.; Ebert, B. L.; Gabriel, S.; Rustgi, A. K.; Antonescu, C. R.; Ladanyi, M.; Letai, A.; Garraway, L. A.; Loda, M.; Beer, D. G.; True, L. D.; Okamoto, A.; Pomeroy, S. L.; Singer, S.; Golub, T.; Lander, E. S.; Getz, G.; Sellers, W. R.; Meyerson, M. The landscape of somatic copy-number alteration across human cancers Nature 2010, 463, 899-905
24. Amundson, S. A.; Myers, T. G.; Scudiero, D.; Kitada, S.; Reed, J. C.; Fornace, A. J., Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines Cancer Res. 2000, 60, 6101-6110
25. L inhibitor Nature Chem. Biol. 2013, 9, 390-397
26. L from NMR and parallel synthesis J. Med. Chem. 2006, 49, 656-663
27. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 2010, 53, 2719-2740
28. L inhibitors in the recent literature. See for example Feng, Y.; Ding, X.; Chen, T.; Chen, L.; Liu, F.; Jia, X.; Luo, X.; Shen, X.; Chen, K.; Jiang, H.; Wang, H.; Liu, H.; Liu, D. J. Med. Chem. 2010, 53, 3465-3479
29. Meerwein, H.; Buchner, E.; van Emster, K. Memorandum from the Chemistry Institute, University of Marburg. The action of aromatic diazo compound on alpha,beta-unsaturated carbonyl bonds J. Prakt. Chem. 1939, 152, 237-266
30. Racane, L.; Tralic-Kulenovic, V.; Boykin, D. W.; Karminski-Zamola, G. Synthesis of new cyano-substituted bis-benzothiazolyl arylfurans and arylthiophenes Molecules 2003, 8, 342-348
31. Han, J. W.; Castro, J. C.; Burgess, K. Microwave-assisted functionalization of bromo-fluorescein and bromorhodamine derivatives Tetrahedron Lett. 2003, 44, 9359-9362
32. Adams, J. M.; Baell, J. B.; Colman, P. M.; Czabotar, P. E.; Huang, D. C. S.; Lessene, G. L.; Sleebs, B. E.; Smith, B. J.; Street, I. P.; Watson, K. G. Benzothiazole compounds. PCT WO2009039553 A1, 2009.
33. Myszka, D. G. Analysis of small-molecule interactions using Biacore S51 technology Anal. Biochem. 2004, 329, 316-323
34. Lee, E. F.; Chen, L.; Yang, H.; Colman, P. M.; Huang, D. C.; Fairlie, W. D. EGL-1 BH3 mutants reveal the importance of protein levels and target affinity for cell-killing potency Cell Death Differ. 2008, 15, 1609-1618
35. Willis, S. N.; Chen, L.; Dewson, G.; Wei, A.; Naik, E.; Fletcher, J. I.; Adams, J. M.; Huang, D. C. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins Genes Dev. 2005, 19, 1294-1305
36. Wendt, M. D.; Shen, W.; Kunzer, A.; McClellan, W. J.; Bruncko, M.; Oost, T. K.; Ding, H.; Joseph, M. K.; Zhang, H. C.; Nimmer, P. M.; Ng, S. C.; Shoemaker, A. R.; Petros, A. M.; Oleksijew, A.; Marsh, K.; Bauch, J.; Oltersdorf, T.; Belli, B. A.; Martineau, D.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo J. Med. Chem. 2006, 49, 1165-1181
37. Mao, H.; Hajduk, P. J.; Craig, R.; Bell, R.; Borre, T.; Fesik, S. W. Rational design of diflunisal analogues with reduced affinity for human serum albumin J. Am. Chem. Soc. 2001, 123, 10429-10435
38. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and its implications for lead optimization Nature Rev. Drug Discovery 2006, 5, 730-739
39. Tummino, P. J.; Copeland, R. A. Residence time of receptor-ligand complexes and its effect on biological function Biochemistry 2008, 47, 5481-5492
40. Verdine, G. L.; Walensky, L. D. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members Clin. Cancer Res. 2007, 13, 7264-7270
41. Berg, T. Small-molecule inhibitors of protein-protein interactions Curr. Opin. Drug Discovery Dev. 2008, 11, 666-674
42. L potentiates the activity of cytotoxic drugs in vitro and in vivo Cancer Res. 2006, 66, 8731-8739
43. Lee, E. F.; Czabotar, P. E.; Yang, H.; Sleebs, B. E.; Lessene, G.; Colman, P. M.; Smith, B. J.; Fairlie, W. D. Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands J. Biol. Chem. 2009, 284, 30508-30517
44. Porter, J.; Payne, A.; De Candole, B.; Ford, D.; Hutchinson, B.; Trevitt, G.; Turner, J.; Edwards, C.; Watkins, C.; Whitcombe, I.; Davis, J.; Stubberfield, C. Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 230-233
45. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
46. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623
47. Hadjuk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. Privileged Molecules for Protein Binding Identified from NMR-Based Screening J. Med. Chem. 2000, 43, 3443-3447
48. Katz, L. Antituberculous Compounds. 111. Benzothiazole and Benzoxazole Derivatives J. Am. Chem. Soc. 1952, 75, 712-714
49. Iemura, R.; Kawashima, T.; Fukuda, T.; Ito, K.; Tsukamoto, G. Synthesis of 2-(4-substituted-1-piperazinyl)benzimidazoles as H1-antihistaminic agents J. Med. Chem. 1986, 29, 1178-1183
50. Czabotar, P. E.; Lee, E. F.; van Delft, M. F.; Day, C. L.; Smith, B. J.; Huang, D. C.; Fairlie, W. D.; Hinds, M. G.; Colman, P. M. Structural insights into the degradation of Mcl-1 induced by BH3 domains Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 6217-6222
51. Lee, E. F.; Czabotar, P. E.; van Delft, M. F.; Michalak, E. M.; Boyle, M. J.; Willis, S. N.; Puthalakath, H.; Bouillet, P.; Colman, P. M.; Huang, D. C.; Fairlie, W. D. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation J. Cell Biol. 2008, 180, 341-355
52. Lee, E. F.; Fedorova, A.; Zobel, K.; Boyle, M. J.; Yang, H.; Perugini, M. A.; Colman, P. M.; Huang, D. C.; Deshayes, K.; Fairlie, W. D. Novel Bcl-2 homology-3 domain-like sequences identified from screening randomized peptide libraries for inhibitors of the pro-survival Bcl-2 proteins J. Biol. Chem. 2009, 284, 31315-31326
53. Zhang, J. H.; Chung, T. D. Y.; Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screening 1999, 4, 67-73